Key Insights

Highlights

Treatment Research

7 treatments under study, led by Laboratory Biomarker Analysis

Research Leaders

5 sponsors active, led by National Cancer Institute (NCI)

Related Conditions

Often studied with 19 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

3 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

3Total
Early Phase 1 (1)
Phase 1 (1)
Phase 2 (1)

Trial Status

Terminated3

Clinical Trials (3)

Showing 3 of 3 trials
NCT02827838Early Phase 1Terminated

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

NCT03090412Phase 2TerminatedPrimary

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT02334319Phase 1Terminated

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Showing all 3 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis3
  • Therapeutic Conventional Surgery3
  • Durvalumab1
  • Hpph1
  • Photodynamic Therapy1

Active Sponsors

  • National Cancer Institute (NCI)2
  • Roswell Park Cancer Institute1
  • Emory University1
  • Wake Forest University Health Sciences1
  • Synta Pharmaceuticals Corp.1

Top Investigators

Related Conditions

  • Stage Ii Oral Cavity Squamous Cell Carcinoma3
  • Stage Iii Oral Cavity Squamous Cell Carcinoma2
  • Stage Iva Oropharyngeal Squamous Cell Carcinoma2
  • Stage I Oropharyngeal Squamous Cell Carcinoma2
  • Stage Iva Oral Cavity Squamous Cell Carcinoma2

Activity Timeline